Drug companies are setting up R&D arms in China, staffing them with local scientists or expat-trained Chinese scientists, to encourage innovative drug research in the country. The GSK R&D center in Shanghai will have a first-year operating budget of $40 million, and AstraZeneca’s Innovation Center China was set up in June 2006 to develop drugs for gastric tract and liver cancers that are prevalent in China.